Fera Pharmaceuticals Announces FDA Orphan Designation of Phospholine Iodide® for the Treatment of Stargardt Disease

NEW YORK--(BUSINESS WIRE)--Fera is pleased to announce that FDA has granted Orphan Drug Designation for Phospholine Iodide (echothiophate iodide for ophthalmic solution) as a treatment for Stargardt disease. “Having only just recently acquired Phospholine Iodide from Pfizer in August, we are excited to work toward extending the utility of this medically important product.” says Frank DellaFera, President of Fera. About Stargardt Disease Stargardt disease is an eye disease that causes vision los